At A Glance
- EloraTZP is a two-drug combination: eloralintide plus tirzepatide, bringing amylin, GIP, and GLP-1 signalling together.
- Retatrutide is one molecule designed to activate GIP, GLP-1, and glucagon receptors.
- EloraTZP’s highest tested combination averaged 23.3% weight reduction at 48 weeks in Phase 2; retatrutide 12 mg averaged 20.8% at 80 weeks in Phase 3.
- The trials were separate. Different designs, doses, timelines, and analysis plans mean the percentages cannot prove that one approach is better.
What Is EloraTZP?
EloraTZP is Lilly’s name for an investigational combination of eloralintide and tirzepatide. Eloralintide is a selective amylin-receptor agonist. Tirzepatide activates GIP and GLP-1 receptors. Put together, the combination reaches three metabolic signalling systems, but it does so with two different molecules rather than one.
In the new Phase 2b study, 367 adults with obesity or overweight and type 2 diabetes were assigned to one of several EloraTZP doses, eloralintide alone, tirzepatide alone, or placebo for 48 weeks. The highest combination—eloralintide 9 mg plus tirzepatide 15 mg—produced the largest reported average change in that study: 23.3% body-weight reduction and a 2.9 percentage-point reduction in A1C. The trial’s main comparison was against placebo, not retatrutide.[1]
How Is EloraTZP Different From Retatrutide?
Both strategies bring three metabolic signals into the discussion, but the third signal is different. EloraTZP adds the amylin pathway to tirzepatide’s GIP and GLP-1 activity. Retatrutide combines glucagon, GIP, and GLP-1 receptor activity in a single molecule.
A simple way to picture it: EloraTZP is a duet—two molecules working through complementary routes. Retatrutide is a three-part harmony built into one molecule. That design difference may affect weight, glucose, energy use, appetite, tolerability, manufacturing, and dose escalation, but receptor count alone cannot tell us which complete profile is better.
The Phase 2 EloraTZP components were given as separate injections. Lilly says an optimized co-formulation is planned for Phase 3, so the final clinical product and schedule may not match the Phase 2 setup.[1]
Did EloraTZP Beat Retatrutide?
No—not in a scientific head-to-head sense. The viral comparison places 23.3% beside 20.8%, but those values came from different studies. EloraTZP was tested for 48 weeks in a smaller Phase 2 trial. Retatrutide was tested for 80 weeks in a larger Phase 3 trial. The studies also used different randomization schemes, dose-escalation plans, comparators, statistical analyses, and participant groups.
The fairest headline is that EloraTZP produced a striking early signal that justifies Phase 3 testing. Retatrutide has the more mature evidence package today. A direct randomized comparison—or at least closely aligned trials—would be needed before calling either strategy the winner.
EloraTZP And Retatrutide At A Glance
The top-line values are useful context, not a leaderboard.
| Question | EloraTZP | Retatrutide | Why it matters |
|---|---|---|---|
| Design | Eloralintide + tirzepatide; two molecules targeting amylin, GIP, and GLP-1 pathways | One molecule targeting glucagon, GIP, and GLP-1 receptors | Both reach three signals, but through different biology and product designs |
| Current headline study | Phase 2b; 367 adults; 48 weeks; obesity or overweight with type 2 diabetes | Phase 3 TRIUMPH-2; 1,152 adults; 80 weeks; obesity or overweight with type 2 diabetes | Retatrutide’s evidence is later-stage, larger, and longer |
| Top reported weight result | 23.3% average reduction with eloralintide 9 mg + tirzepatide 15 mg | 20.8% average reduction with retatrutide 12 mg | These are separate trials and cannot establish superiority |
| A1C result | 2.9 percentage-point reduction at the highest combination | 1.5 percentage-point reduction at 12 mg | Different baselines, durations, and analyses prevent a clean ranking |
| Tolerability signal | GI effects were common; adverse-event discontinuation ranged from 10.8% to 27.0% across combination groups | GI effects were common; adverse-event discontinuation ranged from 3.8% to 11.6% across doses | Dose escalation and trial design can change these rates; they are not head-to-head |
| Development status | Investigational; Phase 3 co-formulation program planned | Investigational; Phase 3 program reported and U.S. submission planned | Neither is established as an approved human-use product on these data alone |
Which Result Is More Established?
Retatrutide’s result is more established right now. TRIUMPH-2 is a Phase 3 trial with 1,152 participants and an 80-week treatment period, and Lilly reported that the findings were published in The Lancet. EloraTZP’s result comes from a 367-person Phase 2b trial announced by the sponsor. That does not make the EloraTZP signal unimportant—it means it needs replication in a larger, later-stage program.
The biggest EloraTZP question is whether the 23.3% result holds up when the combination is co-formulated, tested in more participants, and followed longer. The biggest retatrutide questions concern its complete benefit-risk profile across the broader Phase 3 program and regulatory review.
For now, the sensible read is: EloraTZP may be a serious future competitor, while retatrutide currently has the stronger clinical evidence.
Common Questions About EloraTZP And Retatrutide
Is EloraTZP a single molecule?+
No. It combines two investigational agents: eloralintide and tirzepatide. In Phase 2 they were administered as separate injections; an optimized co-formulation is planned for Phase 3.
Does 23.3% mean EloraTZP is stronger than retatrutide?+
Not by itself. The 23.3% and 20.8% figures came from separate trials with different durations, sample sizes, protocols, and analysis plans. They are useful signals, not a controlled comparison.
Which has the stronger evidence today?+
Retatrutide. Its headline result comes from a larger and longer Phase 3 trial. EloraTZP’s new result is Phase 2b and still needs later-stage confirmation.
Why might the amylin pathway matter?+
Amylin participates in meal-related signalling, including fullness and gastric emptying. Pairing an amylin agonist with GIP and GLP-1 activity offers a different biological route from adding glucagon activity, but clinical trials must show whether that difference produces a better overall result.
Are EloraTZP or retatrutide approved medicines?+
Both remain investigational based on the current development reports. Trial findings do not make an online material equivalent to an authorized finished drug.
Sources
These are the sponsor’s official trial reports and the public study records. Sponsor announcements provide timely top-line results; registries show the planned study design and status.
- Lilly’s EloraTZP combination of eloralintide and tirzepatide delivered 23.3% weight loss in Phase 2Eli Lilly and Company · 2026
Official sponsor report for the 48-week Phase 2b results, including body-weight, A1C, tolerability, and Phase 3 development plans.
- A Study of Eloralintide and Tirzepatide in Participants With Obesity or Overweight and Type 2 DiabetesClinicalTrials.gov · 2026
Public registry record for the EloraTZP Phase 2 study, including enrollment, interventions, eligibility, and outcome measures.
- Lilly’s triple agonist retatrutide delivered substantial weight loss and A1C reductions in TRIUMPH-2Eli Lilly and Company · 2026
Official sponsor report for the 80-week Phase 3 results, including weight, A1C, adverse events, and discontinuations.
- A Study of Retatrutide in Participants With Obesity and Type 2 DiabetesClinicalTrials.gov · 2026
Public registry record for TRIUMPH-2, showing the Phase 3 design, enrollment, interventions, and outcome measures.